Table 1.
Baseline characteristics of patients with AM (n = 79) and in the control group (C, n = 937).
| Baseline characteristics | AM | C | p-Value |
|---|---|---|---|
| Age (years), mean (SD) | 73.7 (13.5) | 71.2 (14.0) | 0.130 |
| Sex (male) | 31 (39.2) | 460 (49.1) | 0.092 |
| History | |||
| Hypertension | 51 (64.6) | 713 (76.1) | 0.023 |
| Diabetes | 25 (31.6) | 251 (26.8) | 0.351 |
| Atrial fibrillation | 33 (41.8) | 297 (31.7) | 0.066 |
| Coronary artery disease | 22 (27.8) | 167 (17.8) | 0.028 |
| Peripheral artery disease | 9 (11.4) | 67 (7.2) | 0.169 |
| Prior stroke | 20 (25.3) | 197 (21.0) | 0.371 |
| Prior TIA | 2 (2.5) | 41 (4.4) | 0.434 |
| Admission | |||
| Large vessel occlusion | 45 (57.0) | 444 (47.4) | 0.102 |
| NIHSS | 11 (5–18) | 9 (4–16) | 0.078 |
| D-dimer (mg/l) | 3.5 (1.5–7.3) a | 1.2 (0.6–3.2) c | <0.001 |
| International normalized ratio | 1.07 (1.01–1.20) b | 1.03 (0.99–1.10) d | 0.001 |
| Activated partial thromboplastin time (s) | 24,5 (22.9–27.5) | 24,8 (23.1–26.8) | 0.668 |
| Hemoglobin (g/dl) | 11,3 (9.8–12.8) | 13,3 (12.1–14.5) | <0.001 |
| Thrombocytes (/nl) | 249.0 (189.0–311.0) | 237.0 (192.0–287.0) | 0.002 |
| Prior antithrombotic treatment | |||
| Single platelet inhibition | 23 (29.1) | 296 (31.6) | 0.706 |
| Dual platelet inhibition | 4 (5.1) | 13 (1.4) | 0.037 |
| Oral anticoagulant | 10 (12.7) | 104 (11.1) | 0.855 |
Data are n (%) or median (interquartile range) if not indicated otherwise.
Data available in an = 64; bn = 77 (AM group); cn = 869; dn = 932 (control group).
AM, active malignancy; C, control group; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack.